NanoPhoria Secures Largest Italian Biotech €83.5M Series A to Advance Heart Failure Therapy

NanoPhoria Bioscience, a Milan-based biotech company, has secured €83.5 million ($97.4 million) in its Series A financing round, marking the largest such round ever for an Italian biotech startup. The round was led by XGEN Venture, Sofinnova Partners, and CDP Venture Capital, with participation from Panakès Partners and an undisclosed investor. The funds will accelerate the clinical development of NanoPhoria's lead candidate, NP-MP1, a first-in-class peptide delivered via a proprietary lung-to-heart nano-in-micro platform targeting cardiac L-type calcium channels to improve ejection fraction for heart failure with reduced ejection fraction (HFrEF). This innovative delivery technology enables targeting of previously inaccessible cellular targets in cardiomyocytes, offering potential life-changing therapies for patients with serious cardiac and chronic conditions. The financing also supports scaling up manufacturing and regulatory programs, as well as expanding the company’s pipeline to pursue indications beyond HFrEF. Industry leaders highlight NanoPhoria's novel approach and strong potential to redefine therapeutic paradigms in cardiovascular and other chronic diseases, underscoring significant investor confidence in the company’s science and platform.